Stockscreener 앱 받기
3.65
0.54%
-0.02
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
A roughly 5% fully diluted stake and a pre-merger cash dividend are expected for Fulcrum (FULC) holders. - Stock Titan
Halper Sadeh LLC is Investigating Whether CSR, FULC, WEAV, PSNL are Obtaining Fair Deals for their Shareholders - globenewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - Supply Chain Digital Magazine
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewswire Inc.
Fulcrum Therapeutics (FULC) Edges Higher to $3.79 as Shares Test Upper RangeJelly Roll Trade - dars.gov.et
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law Violations - NewMediaWire
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inv - The National Law Review
Halper Sadeh LLC is Investigating Whether CSR, EFSI, FULC, TECH are Obtaining Fair Deals for their Shareholders - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ... - pmg-ky3.com
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to an Ongoing Investigation Into Possible Securities Law Violations - NewMediaWire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - globenewswire.com
Halper Sadeh LLC is Investigating Whether FULC, ATKR, FNWD are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inves - The National Law Review
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Collapse - kalkine.ca
TOIIW Warrant Holds Flat at $0.05 as The Oncology Institute Awaits CatalystsBuy Signal Reports - careplusvn.com
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations - The National Law Review
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations - NewMediaWire
Greg Tourangeau, Former Fulcrum Therapeutics Officer, to Sell 14,062 Shares Worth $54,420 - kalkinemedia.com
Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics After 51% Stock Collapse - kalkine.ca
Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock - Stock Titan
Fulcrum (NASDAQ: FULC) plans special cash dividend ahead of Slate Medicines merger - Stock Titan
Kaplan Fox Initiates Securities Probe Into Fulcrum Therapeutics Following 51% Stock Plunge - Kalkine Media
Fulcrum Therapeutics Inc. (FULC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - The Globe and Mail
Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Programme Discontinuation Triggers 51% Stock Drop - kalkine.ca
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? - Yahoo Finance
Fulcrum (FULC) Close: Ends Up by 0.26% at $3.84; Chart View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionVolatility Smile - vinanet.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corpo - mykxlg.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
Fulcrum Therapeutics Stock Drops 51% After Pociredir Discontinuation Triggers Securities Investigation - kalkine.ca
Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? - Morningstar
Fulcrum (FULC) Stock: Falls 0.52% to $3.83 at the Close; Chart View: Support at $3.64 and Resistance at $4.02 Frame the Range in the Latest SessionAnalyst Upgrade Stocks - vinanet.vn
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - PR Newswire
Fulcrum (FULC) Quarter in Focus: The Available Earnings Metric Delivers a Beat in the Current Update; Market Response: Shares Finish 1.03% Higher on the DayEarnings Revision Report - vinanet.vn
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc.FULC - Business Wire
Fulcrum Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Slate Medicines to Merge With Fulcrum Therapeutics - Cooley
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations - FinancialContent
Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating - Moomoo
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - Sahm
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - Sahm
Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger - Legal Desire
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger - Latham & Watkins LLP
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com South Africa
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate - Stock Titan
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement with Key Financial Details - Kalkine Media
Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play - finance.biggo.com
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
4.22%
자본화:
|
볼륨(24시간):